Making Liquid Biopsies Better: How Priming Agents Temporarily Slow Down DNA Clearance

 Introduction:

Researchers are making strides in the field of liquid biopsies, a method that utilizes blood samples for tumor analysis, providing a less invasive alternative to surgical procedures. While this approach has shown promise, detecting circulating tumor DNA (ctDNA) in the bloodstream remains challenging due to its scarcity, especially in cases of small tumors. Martin-Alonso and team have tackled this issue by developing two different priming agents that safeguard circulating DNA from destruction, significantly improving the sensitivity of liquid biopsies.

The Challenge:

Liquid biopsies, involving the analysis of cell-free DNA (cfDNA) from blood, have found applications in diagnosing, monitoring, and molecularly profiling diseases. Despite their rapid adoption in various medical fields, there is a need for higher sensitivity, particularly in oncology, where efforts have primarily focused on ex vivo sequencing and analysis methods. The inherent challenge lies in the limited availability of ctDNA in vivo, leaving minimal material for collection and analysis.

The Approach:

The researchers hypothesized that temporarily reducing the clearance of cfDNA in vivo could enhance ctDNA levels in circulation, facilitating easier detection from a blood draw. They developed two intravenous priming agents administered 1 to 2 hours before a blood draw, targeting mechanisms responsible for cfDNA clearance. The first involves nanoparticles acting on cells responsible for cfDNA clearance, while the second employs DNA-binding monoclonal antibodies (mAbs) to protect cfDNA.

Results:

The nanoparticle priming strategy, utilizing a liposomal agent, successfully inhibited cfDNA uptake in vitro and increased cfDNA recovery from blood in healthy mice. Liposomes accumulated in the liver, with resident macrophages extending cfDNA half-life. Simultaneously, DNA-binding mAbs protected double-stranded DNA from nuclease digestion, with engineered mAbs showing increased persistence in circulation and improved cfDNA recovery.

Conclusion:

These priming agents, by modulating cfDNA clearance in vivo, significantly enhanced the sensitivity and robustness of ctDNA testing in mice with tumors. This advancement holds the potential to revolutionize liquid biopsies across clinical applications, akin to how intravenous contrast agents have improved clinical imaging. The researchers anticipate that this concept of using priming agents to transiently attenuate analyte clearance may also enhance testing for other scarce biomarkers in oncology and beyond.